Sagent Pharmaceuticals (SGNT) Misses Q2 EPS by 6c

Sagent Pharmaceuticals (NASDAQ: SGNT) reported Q2 EPS of ($0.01), $0.06 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $77.3 million versus the consensus estimate of $83.28 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals (SGNT) click here.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Senesco Technologies, Inc. (SNT) Reports Q1 EPS of $0.02
• Super Micro Computer (SMCI) now down nearly 20%